Literature DB >> 16321690

Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease.

Peter Marschang1, Guy J Friedrich, Heidi Ditlbacher, Alfons Stoeger, Dieter Zur Nedden, Rudolf Kirchmair, Anton Dienstl, Otmar Pachinger, Josef R Patsch.   

Abstract

BACKGROUND: Cell adhesion molecules (CAM) play an important role in the pathogenesis of atherosclerosis by mediating the binding of leukocytes to the endothelium. Soluble CAM isoforms are known to be elevated in the sera of patients suffering from coronary artery disease (CAD).
METHODS: We measured the concentrations of soluble intercellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin, P-selectin, platelet endothelial cell adhesion molecule-1, and highly sensitive C-reactive protein (hs-CRP) in the blood of 47 CAD patients before and 6 months after starting statin therapy and in 16 untreated CAD patients. The progression of CAD was monitored by calculating the coronary calcium score using electron beam computed tomography.
RESULTS: Soluble P-selectin (92+/-11 ng/ml vs. 59 +/- 4 ng/ml, p < 0.0001) and hs-CRP (0.92 +/- 0.14 mg/dl vs. 0.42 +/- 0.11 mg/dl, p < 0.001) decreased significantly in the statin-treated group compared to baseline levels. None of the other proteins studied showed significant changes. In contrast to hs-CRP, the reduction of soluble P-selectin concentrations correlated directly with the lowering of total cholesterol (r(2) = 0.236, p < 0.005) and inversely with the progression of CAD (r(2) = 0.393, p < 0.0001).
CONCLUSIONS: Our results suggest P-selectin as an additional marker for the beneficial action of statins in patients with CAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16321690     DOI: 10.1016/j.ijcard.2005.01.042

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  P-selectin and subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Suzette J Bielinski; Cecilia Berardi; Paul A Decker; Phillip S Kirsch; Nicholas B Larson; James S Pankow; Michele Sale; Mariza de Andrade; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Christina L Wassel; Joseph F Polak; Michael Y Tsai
Journal:  Atherosclerosis       Date:  2015-02-23       Impact factor: 5.162

2.  Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

Authors:  Carl J Fichtenbaum; Tzu-Min Yeh; Scott R Evans; Judith A Aberg
Journal:  J Clin Lipidol       Date:  2010 Jul-Aug       Impact factor: 4.766

Review 3.  Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials.

Authors:  Mitra Abbasifard; Tahmineh Kandelouei; Saeed Aslani; Bahman Razi; Danyal Imani; Mahdieh Fasihi; F G Cicero; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2022-02-14       Impact factor: 4.473

4.  Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Authors:  Long Wang; Jason Rockwood; Danielle Zak; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

5.  Association between Endothelial Biomarkers and Arterial Elasticity in Young Adults - The CARDIA Study.

Authors:  Narayanan I Valappil; David R Jacobs; Daniel A Duprez; Myron D Gross; Donna K Arnett; Stephen Glasser
Journal:  J Am Soc Hypertens       Date:  2008 Mar-Apr

Review 6.  Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Tahmineh Kandelouei; Mitra Abbasifard; Danyal Imani; Saeed Aslani; Bahman Razi; Mahdieh Fasihi; Sajad Shafiekhani; Keyhan Mohammadi; Tannaz Jamialahmadi; Željko Reiner; Amirhossein Sahebkar
Journal:  Mediators Inflamm       Date:  2022-01-28       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.